Advanced search
Publication Cover
Leukemia & Lymphoma Volume 11, 1993 - Issue 5-6
Submit an article Journal homepage
28
Views
28
CrossRef citations to date
0
Altmetric
Original Article

Phase I Trial of the Diphtheria Toxin/Interleukin-2 Fusion Protein DAB486IL-2: Efficacy in Mycosis Fungoides and Other Non-Hodgkin's Lymphomas

Timothy M. Kuzel Department of Medicine, Division of Hematology/Oncology Robert H. Lurie Cancer Center and the VA Lakeside Medical Center, Chicago, Illinois
,
Steven T. Rosen Department of Medicine, Division of Hematology/Oncology Robert H. Lurie Cancer Center and the VA Lakeside Medical Center, Chicago, Illinois
,
Leo I. Gordon Department of Medicine, Division of Hematology/Oncology Robert H. Lurie Cancer Center and the VA Lakeside Medical Center, Chicago, Illinois
,
Jane Winter Department of Medicine, Division of Hematology/Oncology Robert H. Lurie Cancer Center and the VA Lakeside Medical Center, Chicago, Illinois
,
Ellen Samuelson Department of Medicine, Division of Hematology/Oncology Robert H. Lurie Cancer Center and the VA Lakeside Medical Center, Chicago, Illinois
,
Karen Kaul Department of Pathology, Robert H. Lurie Cancer Center and the VA Lakeside Medical Center, Chicago, Illinois
,
Henry H. Roenigk Department of Dermatology, Northwestern University Medical School, Robert H. Lurie Cancer Center and the VA Lakeside Medical Center, Chicago, Illinois
,
Pamela Nylen Seragen, Inc., Hopkinton, Massachusetts, USA
&
Thasia Woodworth Seragen, Inc., Hopkinton, Massachusetts, USA
 show all
Pages 369-377 | Received 28 Feb 1993, Published online: 01 Jul 2009

References

  • Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature 1975; 256: 495–497
  • Kuzel T. M., Winter J. N., Rosen S. T., et al. Monoclonal antibody therapy of lymphoproliferative disorders. Oncology 1990; 4: 77–84
  • Waldmann T. A. The multi-chain interleukin-2 receptor: A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts. JAMA 1990; 263: 272–274
  • Williams D. P., Parker P., Bacha W., et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of diphtheria toxin-related interleukin-2 fusion protein. Prot. Eng. 1987; 1: 493–498
  • Bacha P., Williams D. P., Waters C., et al. Interleukin-2 receptor cytotoxicity: Interleukin-2 receptor-mediated action of a diphtheria toxin-related interleukin-2 fusion protein. J. Exp. Med. 1988; 167: 612–622
  • Waters C. A., Schimke P. A., Snider C. E., et al. Receptor binding requirements for entry of a diphtheria toxin-related interleukin-2 fusion protein into cells. Eur. J. Immunol. 1990; 20: 785–791
  • Kiyokawa T., Shirono K., Hattori T., et al. Cytotoxicity of interleukin-2 toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989; 49: 4042–4046
  • LeMaistre C. F., Meneghetti C., Rosenblum M., et al. Phase I trial of an IL-2 fusion toxin (DAB486IL-2) in hema-tologic malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547–2554
  • Rubin L. A., Kurman C. O., Fritz M. E., et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 1985; 135: 3172–3177
  • Steis R. G., Marcon L., Clark J., et al. Serum soluble IL-2R receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988; 71: 1304–1309
  • Motoi T., Uchiyama T., Hori T., et al. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood 1989; 74: 1052–1057
  • Yamaguchi K., Hishimur Y., Kiyokawa T., et al. Elevated serum levels of soluble interleukin-2 receptors in HTLV-1 associated myelopathy. J. Lab. Clin. Med. 1989; 114: 407–410
  • Kay N. E., Burton J., Wagner D., et al. The malignant B-cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. Blood 1988; 72: 447–450
  • Zambello R., Pizzolo G., Trentin L., et al. Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes. Cancer 1989; 64: 2019–2028
  • Semenzato G., Foa R., Agostini C., et al. High Serum levels of soluble interleukin-2 receptor in patients with Bchronic lymphocytic leukemia. Blood 1987; 70: 396–400
  • Ambrosetti A., Semenzato G., Prior M., et al. Serum levels of soluble interleukin-2 receptor in hairy cell leukemia: A reliable marker of neoplastic bulk. Br. J. Haematol. 1989; 73: 181–186
  • Marcon L., Rubin L. A., Kurman C. C., et al. Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: Correlation with clinical status during chemotherapy. Ann. Intern. Med. 1988; 109: 274–279
  • Platanias L. O., Ratain M. J., O'Brien S., et al. Phase I Study of DAB486 IL-2 in patients with hematologic malignancies. Proc. Am. Soc. Clin. Oncol. 1992; 11: 258, (abstr. 843)
  • Hesketh P., Caguioa P., Koh H., et al. Clinical utility of a cytotoxic fusion protein (DAB486IL-2) in the treatment of cutaneous non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. 1992; 11: 317, (abstr. 1076)
  • Woodworm T. G., Nichols J., Recombinant C. fusion toxins—a new class of targeted biologic agents. Cancer Treatment and Research Series Immunoconjugale Therapy of Hematologic Malignancies, S. T. Rosen, T. M. Kuzel. Kluwer Academic Publishers, Norwell, MA, in press
  • Ledermann J. A., Begent R. H. J., Riggs S. R., et al. Suppression of the human anti-mouse antibody response by cyclosporin A during therapy with a monoclonal antibody. Proc. 3rd Int. Conf. on Monoclonal Antibody Immunoconj for Cancer 1988; 3: 15, (abstr. 26)
  • LoBuglio A. F., Khazaeli M., Wheeler R., et al. The effects of immunosuppressive regimens on human immune response to murine monoclonal anti-melanoma antibody-ricin-A chain. Proc. 3rd Int. Conf. on Monoclonal Antibody Immunoconj for Cancer 1988; 3: 15, (abstr. 27)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.